IBIsabel Brosius

Isabel Brosius

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabel Brosius has a total of 281 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phylogenetic analysis of the 2025 Ebola outbreak in the Democratic Republic of the Congo

    by Adrienne Amuri-Aziza, Gradi Luakanda-Ndelemo, Jean-Claude Makangara-Cigolo, Eddy Kinganda-Lusamaki, Christian Ngandu, Serge Bula-Loso, Mathias Mossoko, Louis Tshulo, Prince Akil-Bandali, Richard Kitenge-Omasumbu, et al.

    On 4 September 2025, the Ministry of Public Health, Hygiene and Social Welfare officially declared the 16th Ebola disease outbreak in the Democratic Republic of the Congo (DRC). This outbreak ended on 1 December 2025 and occurred in Bulape Health Zone, Kasaï Province, an area with limited access to appropriate healthcare facilities and resources. Here, we describe the probable index patient and molecular investigations of samples obtained from six suspected patients from the initial outbreak phase. We identified Orthoebolavirus zairense (EBOV) in five samples from different patients. In addition, we performed whole-genome sequencing and generated four complete EBOV genomes. These genomes form a well-supported phylogenetic cluster with genomes from the 1976 Yambuku/Mayinga outbreak. This study suggests a likely new zoonotic spillover event from an as-yet unidentified natural reservoir. While the close relationship to 1976 EBOV Yambuku/Mayinga genomes is striking, this poses additional challenges on the comprehension of the animal reservoir species.


  • Open Access

    Clinical Features and Outcomes Associated with a Clade IIb Mpox Virus Outbreak in Sierra Leone, Jan-Aug 2025

    by Darlinda F. Jiba, Elise De Vos, Eugene Bangwen, Agnes Dora Bangura, Sahr Foday, Joseph Baio Kamara, James Sylvester Squire, Mohamed Boie Jalloh, Daniel Sesay, Ibrahim Franklyn Kamara, et al.

    Background: Several lineages of mpox virus associated with sustained human-to-human transmission have recently caused major outbreaks worldwide. Following its emergence in Nigeria in 2017, Clade IIb caused a global outbreak in 2022 that primarily affected high-income countries and was characterised by low mortality and transmission within sexual networks of men who have sex with men. In January 2025, a large outbreak caused by Clade IIb mpox virus was declared in Sierra Leone. Here, we describe the clinical features and outcomes of individuals affected during this outbreak.Methods: We conducted a secondary analysis of routinely collected outbreak surveillance and clinical data from two mpox referral centers in Freetown, Sierra Leone. Individuals with PCR-confirmed mpox between Jan 10 and Aug 17, 2025 were included.Findings: Data were available for 1,084 individuals with confirmed mpox, 611 (56.4%) men and 472 (43.5%) women. Most cases were individuals aged 15–30 years (528/1084, 48.7%). HIV infection was present in 153 (14.1%) individuals, of whom 105 (68.6%) were newly diagnosed, and over half had CD4 counts ≤200 cells/μL. Genital lesions were reported in 904 (83.5%). Overall mortality was 3.0% (33/1084). Deaths were strongly concentrated among people living with HIV (29/153, 19.0%) compared with those without HIV (4/931, 0.4%) and occurred mainly in individuals with CD4 counts below ≤200 cells/μL. HIV infection was associated with substantially higher odds of mortality (causal odds ratio 47.96, 95% CI 18.93–155.76).Interpretation: During the 2025 outbreak in Sierra Leone, Clade IIb mpox appeared to spread predominantly through heterosexual contact and was associated with substantially higher mortality than reported during the 2022 global outbreak. Death occurred mainly among people living with HIV with advanced immunosuppression. Strengthening health systems, integrating mpox prevention and care with HIV services, and expanding targeted vaccination strategies are essential to reduce spreading and mortality in future outbreaks.

  • Open Access

    The risk of Mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo

    by Megan O&Apos;Driscoll, Elise De Vos, Levi Bugwaja, Isabel Brosius, Sabin S. Nundu, Patrick Musole Bugeme, Justin Bengehya, Trust Faraja Mukika, Patrick Kazuba Bugale, Tony Wawina-Bokalanga, et al.

    Background: Environmental viral burden is a recognized challenge for DNA viruses, with highly sensitive qPCR assays capable of detecting monkeypox virus (MPXV) DNA in the absence of viable virus. The impact of such environmental burden on routine mpox diagnosis and case ascertainment during outbreaks has not previously been quantified. Methods: We collected cycle threshold (Ct) values from 2,724 qPCR-tested persons with mpox compatible illness attending mpox treatment centers across four locations in the Democratic Republic of the Congo and conducted surface sampling of clinic and laboratory environments at two locations. We developed a Bayesian latent class model to distinguish qPCR-positive results of true MPXV infections from those consistent with environmentally-derived MPXV DNA. We estimated the proportion of qPCR-positive results attributable to environmental viral burden by clinical and demographic factors and diagnostic Ct thresholds. Model-based classifications were externally evaluated using longitudinal serologic data from a subset of participants. Findings: We estimate that 35% (95%CrI: 31-39%) of qPCR results with Ct<40, were consistent with environmental burden of MPXV DNA, rather than true infection. Among a subset of participants with serological data, 76% (13/17) of those inferred as environmentally-derived false positives had no serologic evidence of orthopoxvirus infection compared to 0% in those inferred as likely true infections (0/5). Lowering the diagnostic threshold to Ct<37 reduced the false positive proportion to 8% (95% CrI: 7–9%) and to 2% (95% CrI: 1–3%) at Ct<34, with only marginal losses in sensitivity. Interpretation: More than one in three qPCR-positive mpox diagnoses in high-burden settings may have been driven by environmental viral burden, with serological data independently supporting this finding. Strengthened decontamination of clinical areas, lower Ct thresholds, and additional investigation of high-Ct specimens, including clinical progressions, epidemiologic links, and repeat testing, could substantially improve diagnostic specificity while preserving sensitivity.

  • Open Access

    Prevalence, Characteristics and Evolution of Mpox-Related Ophthalmic Disease: A Prospective Cohort Study in South-Kivu, Democratic Republic of the Congo (MBOTE-EYE)

    by Theophile Kabesha, Christophe Van Dijck, Samuel Mudwanga, Sarah Houben, Yves Mujula, Papy Munganga, Jean-Claude Tshomba, Guy Mukari, Tony Wawina-Bokalanga, Eddy Kinganda-Lusamaki, et al.

    Background: Mpox-related ophthalmic disease (MPOXROD) ranges from mild conjunctivitis to sight-threatening keratitis, however, data based on systematic ophthalmological assessment are scarce. We aimed to characterise the prevalence, features, and temporal evolution of MPOXROD during a clade Ib mpox outbreak. Methods: We conducted MBOTE-EYE, a prospective ophthalmological sub-study, nested within a clinical characterisation cohort in Kamituga, South-Kivu, Democratic Republic of the Congo. All hospitalised patients with mpox confirmed by PCR in the prior 48 hours were eligible. Participants underwent comprehensive ophthalmological examination at enrolment, discharge, and days 29 and 59 post-diagnosis. Conjunctival swabs were collected for monkeypox virus PCR testing. MPOXROD was defined as conjunctivitis, scleritis, keratitis, uveitis, or optic nerve involvement. Risk factors were assessed using mixed-effects Poisson regression. Findings: Between 28 October 2024 and 30 June 2025, 310 participants were enrolled (median age 14 years, IQR 2.5-25.0; 53.5% female, n=166/310). At enrolment, conjunctivitis was present in 36.1% (95% CI 31.0–41.6%, n=112/310), keratitis in 7.7% (95% CI 5.3–11.3%), and anterior uveitis in 0.6% (95% CI 0.2–2.3%). Overall, 43.2% (95% CI 37.8–48.8%) developed MPOXROD during follow-up, most often bilaterally. Visual acuity <8/10 occurred in 22.9% (95% CI 17.6–29.2%, n=24/310), and persistent blindness in 0.9% (95% CI 0.24–5.5%, n=2/225), due to ulcerative keratitis. Periorbital lesions (adjusted risk ratio [aRR] 2.82, 95% CI 1.40–5.69) and severe malnutrition (aRR 5.06, 2.25–11.38) were independently associated with MPOXROD. Conjunctival swabs with PCR Ct values < 25 occurred exclusively in participants with active MPOXROD. Interpretation: Ophthalmic involvement in clade Ib mpox is common and frequently bilateral, with a substantial burden of keratitis and risk of vision loss, particularly in young children and severely malnourished individuals. These findings highlight the need for systematic eye examinations in mpox care and provide critical evidence to inform future trials of targeted ophthalmic therapies. Funding: None of the funders had a role in study design, analysis, interpretation, or writing.


  • Open Access

    Epidemiological characteristics of monkeypox virus Clade Ib in the Democratic Republic of the Congo

    by Cécile Kremer, Sabin Sabiti Nundu, Emmanuel Hasivirwe Vakaniaki, Isabel Brosius, Guy Mukari, Papy Munganga, Eugene Bangwen, Jean Claude Tshomba, Yves Mujula, Elise De Vos, et al.

    Monkeypox virus (MPXV) Clade Ib, a new MPXV subclade associated with sustained human-to-human transmission, emerged in eastern DRC in late 2023. Early spread mainly occurred among the adult population, primarily through sexual contact. We investigate how key epidemiological characteristics of the new MPXV Clade Ib outbreak in the DRC differ by transmission mode. We estimate the mean serial interval to be 8.57 days (95% CI 7.15 − 9.91 days). The serial interval is approximately four days shorter for putative sexual compared to non-sexual transmission. We estimate the mean incubation period to be 9.56 days (95% CrI 8.22 − 11.02 days), and approximately two days shorter for putative sexual compared to non-sexual transmission. These observed differences in serial interval and incubation period estimates by transmission mode suggest that the context in which an outbreak occurs is an essential factor to consider when devising public health policies.


  • Open Access

    Three Cases of Vertical Transmission of Clade Ib Mpox Virus

    by Emmanuel Hasivirwe Vakaniaki, Nono-Raymond Swar Kuispond, Yuichiro Hirata, Eugene Bangwen, Isabel Brosius, Eddy Kinganda-Lusamaki, Seiya Ozono, Harutaka Katano, Laurent Gabanga Ndunge, Noella Mulopo-Mukanya, et al.


  • Open Access

    Epidemiological characteristics of mpox virus Clade Ib in the Democratic Republic of the Congo: the impact of transmission mode

    by Cécile Kremer, Sabin Sabiti Nundu, Emmanuel Hasivirwe Vakaniaki, Isabel Brosius, Guy Mukari, Papy Munganga, Eugene Bangwen, Jean Claude Tshomba, Yves Mujula, Elise De Vos, et al.

    Monkeypox virus (MPXV) Clade Ib, a new MPXV subclade associated with sustained human-to-human transmission, emerged in eastern DRC in late 2023. Early spread mainly occurred among the adult population, primarily through sexual contact. We investigated how key epidemiological characteristics of the new MPXV Clade Ib outbreak in the DRC differ by transmission mode. We estimated the mean serial interval to be 8.57 days (95% CI 7.15 – 9.91 days). The serial interval was approximately four days shorter for putative sexual compared to non-sexual transmission. We estimated the mean incubation period to be 9.56 days (95% CrI 8.22 – 11.02 days), and approximately two days shorter for putative sexual compared to non-sexual transmission. These observed differences in serial interval and incubation period estimates by transmission mode suggest that the context in which an outbreak occurs is an essential factor to consider when devising public health policies.


  • Open Access

    No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients

    by Eugene Bangwen, Nicole Berens‐Riha, Nicky de Vrij, Ann Ceulemans, Isabel Brosius, Elise De Vos, Thao‐Thy Pham, Emmanuel Bottieau, Johan van Griensven, Palmer Masumbe Netongo, et al.

    Previous studies indicated Clade I monkeypox virus infection to be associated with marked elevation of proinflammatory cytokines. This remains unexplored for Clade II‐associated disease, which has different clinical manifestations and prognosis. We used a 65‐plex cytokine, chemokine, and growth factor (CCG) panel to analyze serum samples of 100 male acute Clade IIb mpox patients and 26 healthy controls in Belgium. Cluster analyses revealed no strong or distinct CCG profiles distinguishing mpox patients from controls but suggested trends in certain cytokine modulation. Individual CCG analyses found elevated levels of cytokines (MIF, CD30, IL2R, IL18, APRIL, and TNFRII), chemokines (CCL4, CCL8, CCL22, CCL24, CXCL9, CXCL10, CXCL11, CXCL12, and CXCL13), and growth factors (HGF and VEGFA) in patients, while CCL11 and CXCL5 were significantly suppressed. We detected no differences in key proinflammatory cytokines, IL‐1α, IL‐1β, IL‐6, IL‐8 or anti‐inflammatory cytokines, IL‐4, IL‐10, IL‐13. In patients living with HIV, comparison with pre‐outbreak samples showed an increase in CXCL13 and a decrease in CXCL5, CCL2, CCL24, HGF, SCF, and TWEAK. The absence of discriminatory CCG profiles in Clade IIb mpox patients compared to healthy controls suggests there may be limited clinical applications of those markers.


  • Open Access

    Epidemiological and Clinical Features of Mpox during the Clade Ib Outbreak in South-Kivu, Democratic Republic of the Congo: a Prospective Cohort Study

    by Isabel Brosius, Emmanuel Hasivirwe Vakaniaki, Guy Mukari, Papy Munganga, Jean Claude Tshomba, Elise De Vos, Eugene Bangwen, Yves Mujula, Achilleas Tsoumanis, Christophe Van Dijck, et al.

    Background: Clade Ib, a new strain of the Clade I monkeypox virus, emerged in Eastern Democratic Republic of the Congo, sparking an international outbreak. Comprehensive studies are needed to assess its transmission dynamics and clinical presentation. Methods: We conducted a prospective observational cohort study at Kamituga General Hospital in South Kivu, DRC, between May 2 and October 9, 2024. Sociodemographic, exposure and clinical data were collected from mpox suspected cases. Cases confirmed by Xpert® Mpox PCR were presumed Clade Ib infections (awaiting Clade confirmation) and followed through hospitalization and on days 29 and 59 post-diagnosis to assess clinical progression and outcomes. Findings: Of 511 included suspected cases, 431 (84%) tested PCR positive; with 205 being women (47%). Age distribution was bimodal, with 279 (65%) individuals aged 15-34 years, and 63 (15%) children under five. Most cases (59%) reported contact with a suspected or confirmed mpox case; among adults, this was primarily a spouse, colleague or sexual partner, while for children, the primary contacts were parents or siblings. Comorbidities were rare (4%), including six (1%) HIV infections. Prodromal symptoms were present in 346 (88%) patients, active skin lesions in 414 (96%), mucosal lesions in 338 (82%), and lymphadenopathy in 295 (71%). In adults, lesions were more concentrated in the genital area, with 90% of adults presenting lesions in this region. In contrast, only 39% of children had genital lesions, with lesions more frequently found elsewhere on the body. Among 427 hospitalized patients, two deaths (0·5%) occurred. Among 315 patients with detailed hospital follow-up, complications were primarily genito-urinary (55%) or cutaneous (40%). Four of six pregnant women with recorded outcome (67%) had adverse pregnancy outcomes. Significant sequelae at days 29 and 59 were rare. Interpretation: Clade Ib MPXV infections presented differently from previously reported Clade Ia and Clade IIb infections. In adults, the disease primarily affected the genito-urinary system, compatible with sexual transmission, while children mostly manifested extragenital lesions. Funding: European & Developing Countries Clinical Trials Partnership (EDCTP2 and EDCTP3); Belgian Directorate-General Development Cooperation and Humanitarian Aid; Research Foundation – Flanders


  • Top Cited Papers
    Open Access

    Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo

    by Emmanuel Hasivirwe Vakaniaki, Cris Kacita, Eddy Kinganda-Lusamaki, Áine O’tOole, Tony Wawina-Bokalanga, Daniel Mukadi-Bamuleka, Adrienne Amuri-Aziza, Nadine Malyamungu-Bubala, Franklin Mweshi-Kumbana, Léandre Mutimbwa-Mambo, et al.

    Outbreaks of monkeypox (mpox) have historically resulted from zoonotic spillover of clade I monkeypox virus (MPXV) in Central Africa and clade II MPXV in West Africa. In 2022, subclade IIb caused a global epidemic linked to transmission through sexual contact. Here we describe the epidemiological and genomic features of an mpox outbreak in a mining region in eastern Democratic Republic of the Congo, caused by clade I MPXV. Surveillance data collected between September 2023 and January 2024 identified 241 suspected cases. Genomic analysis demonstrates a distinct clade I lineage divergent from previously circulating strains in the Democratic Republic of the Congo. Of the 108 polymerase chain reaction-confirmed mpox cases, the median age of individuals was 22 years, 51.9% were female and 29% were sex workers, suggesting a potential role for sexual transmission. The predominance of APOBEC3-type mutations and the estimated emergence time around mid-September 2023 imply recent sustained human-to-human transmission.